Speciality Medicines Key Ratios
BSE: 544738
₹150.00
₹5.00
(3.45%)
As on 04-Sep-2026IST
Market cap
₹132 Cr
Revenue (TTM)
₹58 Cr
P/E Ratio
10.1
P/B Ratio
1.9
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | 111.71 | 12.95 | -- |
| EBIT | -- | -- | 77.20 | 60.31 | -- |
| Net Profit | -- | -- | 193.43 | 79.86 | -- |
| EPS | -- | -- | 133.29 | 41.75 | -- |
| Book Value | -- | -- | 60.53 | 97.50 | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Mar-25 | Mar-24 | Mar-23 |
| EBIT-Margin
| 15.92 | -- | 15.33 | 18.31 | 14.12 |
| Net Margin
| 10.86 | -- | 14.70 | 10.61 | 7.26 |
| Return on equity
| 36.39 | -- | 37.85 | 28.03 | 43.30 |
| Return on Capital
| 41.53 | -- | 34.47 | 37.72 | 52.41 |
| Return on Assets
| 20.54 | -- | 27.50 | 16.36 | 17.77 |
| Debt to Equity (x)
| -- | -- | 0.17 | 0.19 | 0.62 |
Profitability
ROCE
34.47
Higher than Peers by 30.63
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
34.47
|
37.72
|
52.41
|
69.75
|
--
|
|
Peer Median
|
3.84
|
5.02
|
9.20
|
11.47
|
--
|
ROE
37.85
Higher than Peers by 32.78
Profit after tax / Average Net worth * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
37.85
|
28.03
|
43.30
|
76.56
|
--
|
|
Peer Median
|
5.08
|
1.59
|
9.09
|
3.59
|
--
|
ROA
27.50
Higher than Peers by 25.31
Profit after tax / Average Total assets * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
27.50
|
16.36
|
17.77
|
25.61
|
--
|
|
Peer Median
|
2.19
|
1.46
|
2.77
|
1.32
|
--
|
EBIT Margin
15.33
Higher than Peers by 12.39
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
15.33
|
18.31
|
14.12
|
5.36
|
--
|
|
Peer Median
|
2.93
|
3.78
|
4.14
|
-0.17
|
--
|
Net Margin
14.70
Higher than Peers by 12.74
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
14.70
|
10.61
|
7.26
|
3.66
|
--
|
|
Peer Median
|
1.96
|
3.27
|
13.99
|
1.55
|
--
|
Cash Profit Margin
15.11
Higher than Peers by 15.11
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
15.11
|
11.50
|
8.54
|
3.93
|
--
|
|
Peer Median
|
0.00
|
0.00
|
0.00
|
0.00
|
--
|
Revenue Growth
111.71
Higher than Peers by 60.96
Year on year growth in net sales
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
111.71
|
18.43
|
-42.54
|
--
|
--
|
|
Peer Median
|
50.75
|
56.32
|
1,43,500.00
|
12.18
|
--
|
EBIT Growth
77.20
Higher than Peers by 2.16
Year on year growth in operating profit (EBIT)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
77.20
|
53.55
|
51.42
|
--
|
--
|
|
Peer Median
|
75.04
|
59.55
|
-70.24
|
11.56
|
--
|
Net Profit Growth
193.43
Higher than Peers by 153.48
Year on year growth in profit after tax
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
193.43
|
73.70
|
14.16
|
--
|
--
|
|
Peer Median
|
39.96
|
-8.68
|
-48.33
|
-3.70
|
--
|
EPS Growth
133.30
Higher than Peers by 154.29
Year on year growth in earnings per share
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
133.30
|
29.68
|
-5.86
|
--
|
--
|
|
Peer Median
|
-21.00
|
--
|
--
|
-3.70
|
--
|
Book Value Growth
101.92
--
Year on year growth in book value per share
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
101.92
|
156.66
|
203.73
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.17
--
Total debt / Net worth
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
0.17
|
0.19
|
0.62
|
0.61
|
--
|
|
Peer Median
|
--
|
0.63
|
--
|
--
|
--
|
Short term debt to equity ratio
0.04
--
(Short term borrowings / Net worth)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
0.04
|
0.11
|
0.29
|
0.61
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
5.36
Higher than Peers by 2.89
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
5.36
|
3.12
|
1.83
|
0.93
|
--
|
|
Peer Median
|
2.47
|
2.33
|
5.05
|
5.68
|
--
|
Quick Ratio
2.80
Higher than Peers by 1.13
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
2.80
|
1.92
|
1.09
|
0.80
|
--
|
|
Peer Median
|
1.68
|
10.32
|
6.03
|
5.55
|
--
|
Interest Coverage
18.03
Higher than Peers by 15.37
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
18.03
|
8.39
|
9.33
|
70.21
|
--
|
|
Peer Median
|
2.66
|
2.65
|
2.05
|
5.69
|
--
|
Operating Efficiency
Debtors to sales
16.45
Higher than Peers by 1.08
Debtors outstanding / Net Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
16.45
|
38.92
|
23.69
|
6.41
|
--
|
|
Peer Median
|
15.37
|
42.99
|
49.21
|
11.90
|
--
|
Asset Turnover
1.86
Higher than Peers by 0.35
Sales / Average Total Assets
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
1.86
|
1.53
|
2.44
|
7.00
|
--
|
|
Peer Median
|
1.51
|
1.33
|
0.50
|
1.10
|
--
|
Receivable days
63.57
--
Average Debtors / Sales * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
63.57
|
107.54
|
63.58
|
23.38
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
79.57
--
Average Inventory / Sales * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
79.57
|
83.72
|
39.87
|
4.35
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
14.65
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
14.65
|
42.28
|
33.46
|
12.32
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
128.49
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
128.49
|
148.98
|
70.00
|
15.42
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
65.30
|
159.13
|
107.97
|
115.95
|
--
|
Price / Book Value
--
--
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
2.35
|
3.26
|
2.54
|
2.60
|
--
|
EV/EBITDA
1.13
Lower than Peers by 52.22
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
1.13
|
1.43
|
2.00
|
0.57
|
--
|
|
Peer Median
|
53.35
|
29.43
|
2.43
|
179.61
|
--
|
Market Cap
--
--
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Speciality Medicines
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
30
|
20
|
13
|
13
|
--
|
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
